Last reviewed · How we verify
Ad26.Mos4.HIV
Ad26.Mos4.HIV is a therapeutic HIV vaccine that uses an adenovirus vector to deliver mosaic HIV antigens, stimulating immune responses against diverse HIV strains.
Ad26.Mos4.HIV is a therapeutic HIV vaccine that uses an adenovirus vector to deliver mosaic HIV antigens, stimulating immune responses against diverse HIV strains. Used for HIV-1 infection (therapeutic vaccine in treatment-experienced adults).
At a glance
| Generic name | Ad26.Mos4.HIV |
|---|---|
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine |
| Drug class | Therapeutic HIV vaccine |
| Target | HIV envelope (Env) and Gag proteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine employs a recombinant adenovirus serotype 26 (Ad26) vector expressing mosaic HIV envelope and Gag proteins designed to match global HIV diversity. This approach aims to elicit both cellular and humoral immune responses that can recognize and control multiple HIV variants, potentially reducing viral load and delaying disease progression in HIV-infected individuals.
Approved indications
- HIV-1 infection (therapeutic vaccine in treatment-experienced adults)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults (PHASE1, PHASE2)
- Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults (PHASE1)
- A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (PHASE1, PHASE2)
- Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (PHASE1, PHASE2)
- A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment (PHASE1)
- A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (PHASE3)
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (PHASE1)
- A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |